ID   DAPK1_HUMAN             Reviewed;        1430 AA.
AC   P53355; B7ZLD2; B7ZLE7; Q14CQ7; Q1W5W0; Q68CP8; Q6ZRZ3; Q9BTL8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 6.
DT   10-MAY-2017, entry version 190.
DE   RecName: Full=Death-associated protein kinase 1;
DE            Short=DAP kinase 1;
DE            EC=2.7.11.1;
GN   Name=DAPK1; Synonyms=DAPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INDUCTION,
RP   MUTAGENESIS OF LYS-42, AND VARIANT ASN-1346.
RX   PubMed=7828849; DOI=10.1101/gad.9.1.15;
RA   Deiss L.P., Feinstein E., Berissi H., Cohen O., Kimchi A.;
RT   "Identification of a novel serine/threonine kinase and a novel 15-kD
RT   protein as potential mediators of the gamma interferon-induced cell
RT   death.";
RL   Genes Dev. 9:15-30(1995).
RN   [2]
RP   SEQUENCE REVISION TO 164-171.
RA   Feinstein E.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ASN-1346.
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-591; MET-622;
RP   ASN-1346 AND VAL-1405.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1346.
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-363.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10629061; DOI=10.1128/MCB.20.3.1044-1054.2000;
RA   Inbal B., Shani G., Cohen O., Kissil J.L., Kimchi A.;
RT   "Death-associated protein kinase-related protein 1, a novel
RT   serine/threonine kinase involved in apoptosis.";
RL   Mol. Cell. Biol. 20:1044-1054(2000).
RN   [11]
RP   FUNCTION, ENZYME REGULATION, MUTAGENESIS OF LYS-42; SER-308 AND
RP   SER-313, AND PHOSPHORYLATION AT SER-308.
RX   PubMed=11579085; DOI=10.1074/jbc.M105133200;
RA   Shohat G., Spivak-Kroizman T., Cohen O., Bialik S., Shani G.,
RA   Berissi H., Eisenstein M., Kimchi A.;
RT   "The pro-apoptotic function of death-associated protein kinase is
RT   controlled by a unique inhibitory autophosphorylation-based
RT   mechanism.";
RL   J. Biol. Chem. 276:47460-47467(2001).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11980920; DOI=10.1083/jcb.200109094;
RA   Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A.;
RT   "DAP kinase and DRP-1 mediate membrane blebbing and the formation of
RT   autophagic vesicles during programmed cell death.";
RL   J. Cell Biol. 157:455-468(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF STX1A, AND INTERACTION WITH STX1A.
RX   PubMed=12730201; DOI=10.1074/jbc.M300492200;
RA   Tian J.H., Das S., Sheng Z.H.;
RT   "Ca2+-dependent phosphorylation of syntaxin-1A by the death-associated
RT   protein (DAP) kinase regulates its interaction with Munc18.";
RL   J. Biol. Chem. 278:26265-26274(2003).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF DAPK3, AND INTERACTION WITH DAPK3.
RX   PubMed=15367680; DOI=10.1128/MCB.24.19.8611-8626.2004;
RA   Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G.,
RA   Kimchi A.;
RT   "Death-associated protein kinase phosphorylates ZIP kinase, forming a
RT   unique kinase hierarchy to activate its cell death functions.";
RL   Mol. Cell. Biol. 24:8611-8626(2004).
RN   [15]
RP   INTERACTION WITH PDCD6.
RX   PubMed=16132846; DOI=10.1007/s10529-005-7869-x;
RA   Lee J.H., Rho S.B., Chun T.;
RT   "Programmed cell death 6 (PDCD6) protein interacts with death-
RT   associated protein kinase 1 (DAPk1): additive effect on apoptosis via
RT   caspase-3 dependent pathway.";
RL   Biotechnol. Lett. 27:1011-1015(2005).
RN   [16]
RP   PHOSPHORYLATION AT SER-289.
RX   PubMed=16213824; DOI=10.1016/j.cub.2005.08.050;
RA   Anjum R., Roux P.P., Ballif B.A., Gygi S.P., Blenis J.;
RT   "The tumor suppressor DAP kinase is a target of RSK-mediated survival
RT   signaling.";
RL   Curr. Biol. 15:1762-1767(2005).
RN   [17]
RP   PHOSPHORYLATION AT SER-734, AND INTERACTION WITH MAPK1 AND MAPK3.
RX   PubMed=15616583; DOI=10.1038/sj.emboj.7600510;
RA   Chen C.H., Wang W.J., Kuo J.C., Tsai H.C., Lin J.R., Chang Z.F.,
RA   Chen R.H.;
RT   "Bidirectional signals transduced by DAPK-ERK interaction promote the
RT   apoptotic effect of DAPK.";
RL   EMBO J. 24:294-304(2005).
RN   [18]
RP   PHOSPHORYLATION AT SER-308, ENZYME REGULATION, AND INTERACTION WITH
RP   UNC5B.
RX   PubMed=15729359; DOI=10.1038/sj.emboj.7600584;
RA   Llambi F., Lourenco F.C., Gozuacik D., Guix C., Pays L., Del Rio G.,
RA   Kimchi A., Mehlen P.;
RT   "The dependence receptor UNC5H2 mediates apoptosis through DAP-
RT   kinase.";
RL   EMBO J. 24:1192-1201(2005).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and
RT   beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [20]
RP   ALTERNATIVE SPLICING (ISOFORM 3), PHOSPHORYLATION AT SER-308,
RP   DEPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=17056602; DOI=10.1074/jbc.M605097200;
RA   Jin Y., Blue E.K., Gallagher P.J.;
RT   "Control of death-associated protein kinase (DAPK) activity by
RT   phosphorylation and proteasomal degradation.";
RL   J. Biol. Chem. 281:39033-39040(2006).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF PRKD1, AND INTERACTION WITH PRKD1.
RX   PubMed=17703233; DOI=10.1038/sj.cdd.4402212;
RA   Eisenberg-Lerner A., Kimchi A.;
RT   "DAP kinase regulates JNK signaling by binding and activating protein
RT   kinase D under oxidative stress.";
RL   Cell Death Differ. 14:1908-1915(2007).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF TPM1.
RX   PubMed=17895359; DOI=10.1242/jcs.003251;
RA   Houle F., Poirier A., Dumaresq J., Huot J.;
RT   "DAP kinase mediates the phosphorylation of tropomyosin-1 downstream
RT   of the ERK pathway, which regulates the formation of stress fibers in
RT   response to oxidative stress.";
RL   J. Cell Sci. 120:3666-3677(2007).
RN   [23]
RP   ALTERNATIVE SPLICING (ISOFORM 2), PROTEOLYTIC PROCESSING, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18422656; DOI=10.1111/j.1742-4658.2008.06404.x;
RA   Lin Y., Stevens C., Hrstka R., Harrison B., Fourtouna A., Pathuri S.,
RA   Vojtesek B., Hupp T.;
RT   "An alternative transcript from the death-associated protein kinase 1
RT   locus encoding a small protein selectively mediates membrane
RT   blebbing.";
RL   FEBS J. 275:2574-2584(2008).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAP1B.
RX   PubMed=18195017; DOI=10.1074/jbc.M706040200;
RA   Harrison B., Kraus M., Burch L., Stevens C., Craig A.,
RA   Gordon-Weeks P., Hupp T.R.;
RT   "DAPK-1 binding to a linear peptide motif in MAP1B stimulates
RT   autophagy and membrane blebbing.";
RL   J. Biol. Chem. 283:9999-10014(2008).
RN   [25]
RP   FUNCTION.
RX   PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019;
RA   Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.;
RT   "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating
RT   inflammatory gene expression.";
RL   Mol. Cell 32:371-382(2008).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF BECN1, AND INTERACTION WITH BECN1.
RX   PubMed=19180116; DOI=10.1038/embor.2008.246;
RA   Zalckvar E., Berissi H., Mizrachy L., Idelchuk Y., Koren I.,
RA   Eisenstein M., Sabanay H., Pinkas-Kramarski R., Kimchi A.;
RT   "DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1
RT   promotes dissociation of beclin 1 from Bcl-XL and induction of
RT   autophagy.";
RL   EMBO Rep. 10:285-292(2009).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2 AND RPS6, AND INTERACTION WITH
RP   TSC2.
RX   PubMed=18974095; DOI=10.1074/jbc.M805165200;
RA   Stevens C., Lin Y., Harrison B., Burch L., Ridgway R.A., Sansom O.,
RA   Hupp T.;
RT   "Peptide combinatorial libraries identify TSC2 as a death-associated
RT   protein kinase (DAPK) death domain-binding protein and reveal a
RT   stimulatory role for DAPK in mTORC1 signaling.";
RL   J. Biol. Chem. 284:334-344(2009).
RN   [28]
RP   UBIQUITINATION, AND INTERACTION WITH KLHL20.
RX   PubMed=20389280; DOI=10.1038/emboj.2010.62;
RA   Lee Y.R., Yuan W.C., Ho H.C., Chen C.H., Shih H.M., Chen R.H.;
RT   "The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to
RT   control interferon responses.";
RL   EMBO J. 29:1748-1761(2010).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=19878313; DOI=10.1111/j.1742-4658.2009.07411.x;
RA   Lin Y., Hupp T.R., Stevens C.;
RT   "Death-associated protein kinase (DAPK) and signal transduction:
RT   additional roles beyond cell death.";
RL   FEBS J. 277:48-57(2010).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF PIN1, AND INTERACTION WITH PIN1.
RX   PubMed=21497122; DOI=10.1016/j.molcel.2011.03.005;
RA   Lee T.H., Chen C.H., Suizu F., Huang P., Schiene-Fischer C., Daum S.,
RA   Zhang Y.J., Goate A., Chen R.H., Zhou X.Z., Lu K.P.;
RT   "Death-associated protein kinase 1 phosphorylates Pin1 and inhibits
RT   its prolyl isomerase activity and cellular function.";
RL   Mol. Cell 42:147-159(2011).
RN   [31]
RP   FUNCTION.
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-319, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-333, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 2-285 IN COMPLEX WITH ATP
RP   ANALOG AND DIVALENT METAL CATION.
RX   PubMed=11573098; DOI=10.1038/nsb1001-899;
RA   Tereshko V., Teplova M., Brunzelle J., Watterson D.M., Egli M.;
RT   "Crystal structures of the catalytic domain of human protein kinase
RT   associated with apoptosis and tumor suppression.";
RL   Nat. Struct. Biol. 8:899-907(2001).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2-285 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=14505650; DOI=10.1016/S0960-894X(03)00733-9;
RA   Velentza A.V., Wainwright M.S., Zasadzki M., Mirzoeva S.,
RA   Schumacher A.M., Haiech J., Focia P.J., Egli M., Watterson D.M.;
RT   "An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase
RT   attenuates hypoxia-ischemia induced acute brain injury.";
RL   Bioorg. Med. Chem. Lett. 13:3465-3470(2003).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-278 IN COMPLEX WITH
RP   INHIBITORS.
RA   Ueda Y., Ogata H., Yamakawa A., Higuchi Y.;
RT   "Complex structure of kinase domain of DAP kinase with
RT   staurosporine.";
RL   Submitted (APR-2006) to the PDB data bank.
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 302-320 IN COMPLEX WITH
RP   CALMODULIN.
RA   Kursula P., Vahokoski J., Wilmanns M.;
RT   "Recognition of human death-associated protein kinases by
RT   calmodulin.";
RL   Submitted (JUL-2006) to the PDB data bank.
RN   [39]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-416; SER-461; ALA-519; TYR-540;
RP   THR-941; TRP-977; ASN-978; CYS-993; GLU-994; GLN-1005; TYR-1007;
RP   PRO-1008; CYS-1010; ALA-1018; ILE-1272; ASN-1346 AND VAL-1405.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase
CC       involved in multiple cellular signaling pathways that trigger cell
CC       survival, apoptosis, and autophagy. Regulates both type I
CC       apoptotic and type II autophagic cell deaths signal, depending on
CC       the cellular setting. The former is caspase-dependent, while the
CC       latter is caspase-independent and is characterized by the
CC       accumulation of autophagic vesicles. Phosphorylates PIN1 resulting
CC       in inhibition of its catalytic activity, nuclear localization, and
CC       cellular function. Phosphorylates TPM1, enhancing stress fiber
CC       formation in endothelial cells. Phosphorylates STX1A and
CC       significantly decreases its binding to STXBP1. Phosphorylates
CC       PRKD1 and regulates JNK signaling by binding and activating PRKD1
CC       under oxidative stress. Phosphorylates BECN1, reducing its
CC       interaction with BCL2 and BCL2L1 and promoting the induction of
CC       autophagy. Phosphorylates TSC2, disrupting the TSC1-TSC2 complex
CC       and stimulating mTORC1 activity in a growth factor-dependent
CC       pathway. Phosphorylates RPS6, MYL9 and DAPK3. Acts as a signaling
CC       amplifier of NMDA receptors at extrasynaptic sites for mediating
CC       brain damage in stroke. Cerebral ischemia recruits DAPK1 into the
CC       NMDA receptor complex and it phosphorylates GRINB at Ser-1303
CC       inducing injurious Ca(2+) influx through NMDA receptor channels,
CC       resulting in an irreversible neuronal death. Required together
CC       with DAPK3 for phosphorylation of RPL13A upon interferon-gamma
CC       activation which is causing RPL13A involvement in transcript-
CC       selective translation inhibition.
CC   -!- FUNCTION: Isoform 2 cannot induce apoptosis but can induce
CC       membrane blebbing.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by Ca(2+)/calmodulin. Regulated by a
CC       locking mechanism, involving autophosphorylation at Ser-308 and
CC       calmodulin binding. In the inactive state, Ser-308 is
CC       phosphorylated. Activation involves its dephosphorylation and a
CC       release-of-autoinhibition mechanism where binding of calmodulin
CC       induces a conformational change that relieves the steric block of
CC       the active site by the autoinhibitory domain. Activity is
CC       modulated by UNC5B and NTN1. UNC5B activates it by inhibiting the
CC       phosphorylation at Ser-308, whereas NTN1 inhibits UNC5B-mediated
CC       activation of DAPK1. Endoplasmic-stress activates by causing Ser-
CC       308 dephosphorylation. {ECO:0000269|PubMed:11579085,
CC       ECO:0000269|PubMed:15729359, ECO:0000269|PubMed:17056602}.
CC   -!- SUBUNIT: Interacts with KLHL20. Interacts (via death domain) with
CC       MAPK1 and MAPK3. Interacts with MAP1B (via N-terminus). Interacts
CC       (via death domain) with UNC5B (via death domain). Interacts with
CC       PRKD1 in an oxidative stress-regulated manner. Interacts with
CC       PIN1, PDCD6, BECN1, GRINB, TSC2 and STX1A. Interacts (via kinase
CC       domain) with DAPK3 (via kinase domain).
CC       {ECO:0000269|PubMed:11573098, ECO:0000269|PubMed:12730201,
CC       ECO:0000269|PubMed:14505650, ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15616583, ECO:0000269|PubMed:15729359,
CC       ECO:0000269|PubMed:16132846, ECO:0000269|PubMed:17703233,
CC       ECO:0000269|PubMed:18195017, ECO:0000269|PubMed:18974095,
CC       ECO:0000269|PubMed:19180116, ECO:0000269|PubMed:20389280,
CC       ECO:0000269|PubMed:21497122, ECO:0000269|Ref.37,
CC       ECO:0000269|Ref.38}.
CC   -!- INTERACTION:
CC       Self; NbExp=6; IntAct=EBI-358616, EBI-358616;
CC       Q14457:BECN1; NbExp=4; IntAct=EBI-358616, EBI-949378;
CC       P62158:CALM3; NbExp=6; IntAct=EBI-358616, EBI-397435;
CC       Q9Y2M5:KLHL20; NbExp=11; IntAct=EBI-358616, EBI-714379;
CC       Q38SD2:LRRK1; NbExp=2; IntAct=EBI-358616, EBI-1050422;
CC       Q5S007:LRRK2; NbExp=2; IntAct=EBI-358616, EBI-5323863;
CC       P27361:MAPK3; NbExp=5; IntAct=EBI-358616, EBI-73995;
CC       O75340:PDCD6; NbExp=3; IntAct=EBI-358616, EBI-352915;
CC       P14618:PKM; NbExp=3; IntAct=EBI-358616, EBI-353408;
CC       P14618-1:PKM; NbExp=2; IntAct=EBI-358616, EBI-4304679;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Cytoplasm,
CC       cytoskeleton. Note=Colocalizes with MAP1B in the microtubules and
CC       cortical actin fibers.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Cytoplasm,
CC       cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=P53355-1; Sequence=Displayed;
CC       Name=2; Synonyms=s-DAPK-1;
CC         IsoId=P53355-2; Sequence=VSP_042053, VSP_042054, VSP_042055;
CC       Name=3; Synonyms=Beta;
CC         IsoId=P53355-3; Sequence=VSP_042056;
CC       Name=4;
CC         IsoId=P53355-4; Sequence=VSP_054478;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 2 is expressed in normal intestinal
CC       tissue as well as in colorectal carcinomas.
CC       {ECO:0000269|PubMed:18422656}.
CC   -!- INDUCTION: Up-regulated following treatment with IFNG/IFN-gamma.
CC       {ECO:0000269|PubMed:7828849}.
CC   -!- DOMAIN: The autoinhibitory domain sterically blocks the substrate
CC       peptide-binding site by making both hydrophobic and electrostatic
CC       contacts with the kinase core.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL20) E3 ubiquitin ligase complex,
CC       leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:20389280}.
CC   -!- PTM: Removal of the C-terminal tail of isoform 2 (corresponding to
CC       amino acids 296-337 of isoform 2) by proteolytic cleavage
CC       stimulates maximally its membrane-blebbing function.
CC       {ECO:0000269|PubMed:18422656}.
CC   -!- PTM: In response to mitogenic stimulation (PMA or EGF),
CC       phosphorylated at Ser-289; phosphorylation suppresses DAPK1 pro-
CC       apoptotic function. Autophosphorylation at Ser-308 inhibits its
CC       catalytic activity. Phosphorylation at Ser-734 by MAPK1 increases
CC       its catalytic activity and promotes cytoplasmic retention of
CC       MAPK1. Endoplasmic-stress can cause dephosphorylation at Ser-308.
CC       {ECO:0000269|PubMed:11579085, ECO:0000269|PubMed:15616583,
CC       ECO:0000269|PubMed:15729359, ECO:0000269|PubMed:16213824,
CC       ECO:0000269|PubMed:17056602}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. DAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP35581.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA53712.1; Type=Frameshift; Positions=462, 464; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/dapk1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DAPK1ID417ch9q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X76104; CAA53712.1; ALT_FRAME; mRNA.
DR   EMBL; AK127855; BAC87163.1; -; mRNA.
DR   EMBL; CR749834; CAH18690.1; -; mRNA.
DR   EMBL; DQ436495; ABD96827.1; -; Genomic_DNA.
DR   EMBL; AL160279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161787; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591852; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471089; EAW62727.1; -; Genomic_DNA.
DR   EMBL; BC113660; AAI13661.1; -; mRNA.
DR   EMBL; BC143733; AAI43734.1; -; mRNA.
DR   EMBL; BC143759; AAI43760.1; -; mRNA.
DR   EMBL; BT006935; AAP35581.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS43842.1; -. [P53355-1]
DR   PIR; I37275; I37275.
DR   RefSeq; NP_001275658.1; NM_001288729.1. [P53355-1]
DR   RefSeq; NP_001275659.1; NM_001288730.1. [P53355-1]
DR   RefSeq; NP_001275660.1; NM_001288731.1. [P53355-1]
DR   RefSeq; NP_004929.2; NM_004938.3. [P53355-1]
DR   UniGene; Hs.380277; -.
DR   UniGene; Hs.693441; -.
DR   PDB; 1IG1; X-ray; 1.80 A; A=2-285.
DR   PDB; 1JKK; X-ray; 2.40 A; A=2-285.
DR   PDB; 1JKL; X-ray; 1.62 A; A=2-285.
DR   PDB; 1JKS; X-ray; 1.50 A; A=2-285.
DR   PDB; 1JKT; X-ray; 3.50 A; A/B=2-285.
DR   PDB; 1P4F; X-ray; 1.90 A; A=2-285.
DR   PDB; 1WVW; X-ray; 2.40 A; A=1-278.
DR   PDB; 1WVX; X-ray; 2.60 A; A=1-278.
DR   PDB; 1WVY; X-ray; 2.80 A; A=1-278.
DR   PDB; 1YR5; X-ray; 1.70 A; B=302-320.
DR   PDB; 2W4J; X-ray; 1.30 A; A=1-277.
DR   PDB; 2W4K; X-ray; 1.90 A; A=1-302.
DR   PDB; 2X0G; X-ray; 2.20 A; A=1-334.
DR   PDB; 2XUU; X-ray; 1.80 A; A=1-334.
DR   PDB; 2XZS; X-ray; 2.00 A; A/B=2-312.
DR   PDB; 2Y0A; X-ray; 2.60 A; A=2-304.
DR   PDB; 2Y4P; X-ray; 2.65 A; A/B/C/D=1-285.
DR   PDB; 2Y4V; X-ray; 1.80 A; B=302-320.
DR   PDB; 2YAK; X-ray; 2.20 A; A=1-285.
DR   PDB; 3DFC; X-ray; 1.90 A; B=1-285.
DR   PDB; 3DGK; X-ray; 1.70 A; A=1-285.
DR   PDB; 3EH9; X-ray; 1.70 A; A=2-285.
DR   PDB; 3EHA; X-ray; 1.60 A; A=2-285.
DR   PDB; 3F5G; X-ray; 1.85 A; A=2-285.
DR   PDB; 3F5U; X-ray; 2.00 A; A=1-285.
DR   PDB; 3GU4; X-ray; 1.35 A; A=1-285.
DR   PDB; 3GU5; X-ray; 1.65 A; A=1-285.
DR   PDB; 3GU6; X-ray; 1.49 A; A=1-285.
DR   PDB; 3GU7; X-ray; 1.90 A; A=1-285.
DR   PDB; 3GU8; X-ray; 1.60 A; A=1-285.
DR   PDB; 3GUB; X-ray; 1.71 A; A=1-285.
DR   PDB; 3ZXT; X-ray; 2.65 A; A/B/C/D=1-285.
DR   PDB; 4B4L; X-ray; 1.75 A; A=1-334.
DR   PDB; 4PF4; X-ray; 1.13 A; A=1-277.
DR   PDB; 4TL0; X-ray; 2.70 A; A=1-334.
DR   PDB; 4TXC; X-ray; 1.95 A; A=1-285.
DR   PDB; 4UV0; X-ray; 2.49 A; A=1-321.
DR   PDB; 4YO4; X-ray; 1.60 A; A=2-285.
DR   PDB; 4YPD; X-ray; 1.40 A; A=2-285.
DR   PDB; 5AUT; X-ray; 1.70 A; A=1-285.
DR   PDB; 5AUU; X-ray; 1.70 A; A=1-285.
DR   PDB; 5AUV; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUW; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUX; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AUY; X-ray; 2.00 A; A=1-285.
DR   PDB; 5AUZ; X-ray; 1.60 A; A=1-285.
DR   PDB; 5AV0; X-ray; 1.85 A; A=1-285.
DR   PDB; 5AV1; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AV2; X-ray; 1.50 A; A=1-285.
DR   PDB; 5AV3; X-ray; 1.90 A; A=1-285.
DR   PDB; 5AV4; X-ray; 1.40 A; A=1-285.
DR   PDBsum; 1IG1; -.
DR   PDBsum; 1JKK; -.
DR   PDBsum; 1JKL; -.
DR   PDBsum; 1JKS; -.
DR   PDBsum; 1JKT; -.
DR   PDBsum; 1P4F; -.
DR   PDBsum; 1WVW; -.
DR   PDBsum; 1WVX; -.
DR   PDBsum; 1WVY; -.
DR   PDBsum; 1YR5; -.
DR   PDBsum; 2W4J; -.
DR   PDBsum; 2W4K; -.
DR   PDBsum; 2X0G; -.
DR   PDBsum; 2XUU; -.
DR   PDBsum; 2XZS; -.
DR   PDBsum; 2Y0A; -.
DR   PDBsum; 2Y4P; -.
DR   PDBsum; 2Y4V; -.
DR   PDBsum; 2YAK; -.
DR   PDBsum; 3DFC; -.
DR   PDBsum; 3DGK; -.
DR   PDBsum; 3EH9; -.
DR   PDBsum; 3EHA; -.
DR   PDBsum; 3F5G; -.
DR   PDBsum; 3F5U; -.
DR   PDBsum; 3GU4; -.
DR   PDBsum; 3GU5; -.
DR   PDBsum; 3GU6; -.
DR   PDBsum; 3GU7; -.
DR   PDBsum; 3GU8; -.
DR   PDBsum; 3GUB; -.
DR   PDBsum; 3ZXT; -.
DR   PDBsum; 4B4L; -.
DR   PDBsum; 4PF4; -.
DR   PDBsum; 4TL0; -.
DR   PDBsum; 4TXC; -.
DR   PDBsum; 4UV0; -.
DR   PDBsum; 4YO4; -.
DR   PDBsum; 4YPD; -.
DR   PDBsum; 5AUT; -.
DR   PDBsum; 5AUU; -.
DR   PDBsum; 5AUV; -.
DR   PDBsum; 5AUW; -.
DR   PDBsum; 5AUX; -.
DR   PDBsum; 5AUY; -.
DR   PDBsum; 5AUZ; -.
DR   PDBsum; 5AV0; -.
DR   PDBsum; 5AV1; -.
DR   PDBsum; 5AV2; -.
DR   PDBsum; 5AV3; -.
DR   PDBsum; 5AV4; -.
DR   ProteinModelPortal; P53355; -.
DR   SMR; P53355; -.
DR   BioGrid; 107982; 51.
DR   IntAct; P53355; 33.
DR   MINT; MINT-1136108; -.
DR   STRING; 9606.ENSP00000350785; -.
DR   BindingDB; P53355; -.
DR   ChEMBL; CHEMBL2558; -.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   GuidetoPHARMACOLOGY; 2002; -.
DR   iPTMnet; P53355; -.
DR   PhosphoSitePlus; P53355; -.
DR   BioMuta; DAPK1; -.
DR   DMDM; 317373595; -.
DR   EPD; P53355; -.
DR   MaxQB; P53355; -.
DR   PaxDb; P53355; -.
DR   PeptideAtlas; P53355; -.
DR   PRIDE; P53355; -.
DR   DNASU; 1612; -.
DR   Ensembl; ENST00000358077; ENSP00000350785; ENSG00000196730. [P53355-1]
DR   Ensembl; ENST00000408954; ENSP00000386135; ENSG00000196730. [P53355-1]
DR   Ensembl; ENST00000469640; ENSP00000418885; ENSG00000196730. [P53355-4]
DR   Ensembl; ENST00000472284; ENSP00000417076; ENSG00000196730. [P53355-1]
DR   Ensembl; ENST00000491893; ENSP00000419026; ENSG00000196730. [P53355-4]
DR   Ensembl; ENST00000622514; ENSP00000484267; ENSG00000196730. [P53355-1]
DR   GeneID; 1612; -.
DR   KEGG; hsa:1612; -.
DR   UCSC; uc004apc.5; human. [P53355-1]
DR   CTD; 1612; -.
DR   DisGeNET; 1612; -.
DR   GeneCards; DAPK1; -.
DR   HGNC; HGNC:2674; DAPK1.
DR   HPA; CAB037302; -.
DR   HPA; HPA040472; -.
DR   HPA; HPA048436; -.
DR   MIM; 600831; gene.
DR   neXtProt; NX_P53355; -.
DR   OpenTargets; ENSG00000196730; -.
DR   PharmGKB; PA27142; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; ENOG410XRMJ; LUCA.
DR   GeneTree; ENSGT00760000118877; -.
DR   HOGENOM; HOG000082489; -.
DR   HOVERGEN; HBG051296; -.
DR   InParanoid; P53355; -.
DR   KO; K08803; -.
DR   OMA; IDVQDKG; -.
DR   OrthoDB; EOG091G0J2O; -.
DR   PhylomeDB; P53355; -.
DR   TreeFam; TF314166; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-418889; Ligand-independent caspase activation via DCC.
DR   SignaLink; P53355; -.
DR   SIGNOR; P53355; -.
DR   ChiTaRS; DAPK1; human.
DR   EvolutionaryTrace; P53355; -.
DR   GeneWiki; DAPK1; -.
DR   GenomeRNAi; 1612; -.
DR   PRO; PR:P53355; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196730; -.
DR   CleanEx; HS_DAPK1; -.
DR   ExpressionAtlas; P53355; baseline and differential.
DR   Genevisible; P53355; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0017075; F:syntaxin-1 binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0071447; P:cellular response to hydroperoxide; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; ISS:UniProtKB.
DR   Gene3D; 1.25.40.20; -; 4.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR020676; DAPK1.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR020859; ROC_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR10489:SF789; PTHR10489:SF789; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 9.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 7.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51424; ROC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ANK repeat; Apoptosis;
KW   ATP-binding; Calmodulin-binding; Complete proteome; Cytoplasm;
KW   Cytoskeleton; GTP-binding; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Translation regulation;
KW   Ubl conjugation.
FT   CHAIN         1   1430       Death-associated protein kinase 1.
FT                                /FTId=PRO_0000085910.
FT   DOMAIN       13    275       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REPEAT      378    407       ANK 1.
FT   REPEAT      411    440       ANK 2.
FT   REPEAT      444    473       ANK 3.
FT   REPEAT      477    506       ANK 4.
FT   REPEAT      510    539       ANK 5.
FT   REPEAT      543    572       ANK 6.
FT   REPEAT      576    605       ANK 7.
FT   REPEAT      609    638       ANK 8.
FT   DOMAIN      681    955       Roc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00758}.
FT   REPEAT      875    904       ANK 9.
FT   REPEAT     1162   1196       ANK 10.
FT   DOMAIN     1312   1396       Death. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00064}.
FT   NP_BIND      19     27       ATP.
FT   NP_BIND      94     96       ATP.
FT   REGION      267    334       Calmodulin-binding.
FT   REGION      292    301       Autoinhibitory domain. {ECO:0000250}.
FT   ACT_SITE    139    139       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      42     42       ATP.
FT   BINDING     100    100       ATP.
FT   BINDING     161    161       ATP.
FT   MOD_RES     289    289       Phosphoserine; by RPS6KA1 and RPS6KA3.
FT                                {ECO:0000269|PubMed:16213824}.
FT   MOD_RES     308    308       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11579085,
FT                                ECO:0000269|PubMed:15729359,
FT                                ECO:0000269|PubMed:17056602}.
FT   MOD_RES     319    319       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     333    333       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     734    734       Phosphoserine; by MAPK1.
FT                                {ECO:0000269|PubMed:15616583}.
FT   MOD_RES    1115   1115       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80YE7}.
FT   VAR_SEQ       1    446       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042053.
FT   VAR_SEQ     742    783       VSVSINNLYPGCENVSVRSRSMMFEPGLTKGMLEVFVAPTH
FT                                H -> GRNLHAGPVSPAGVGFRTLSFQGLGGKGVVFGSLGL
FT                                YWTLWP (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042054.
FT   VAR_SEQ     784   1430       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042055.
FT   VAR_SEQ     805    870       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054478.
FT   VAR_SEQ    1430   1430       R -> RRNSHVWNPTV (in isoform 3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042056.
FT   VARIANT     416    416       V -> I (in dbSNP:rs12343465).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_033235.
FT   VARIANT     461    461       A -> S. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040420.
FT   VARIANT     519    519       S -> A. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040421.
FT   VARIANT     540    540       C -> Y (in dbSNP:rs56327474).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040422.
FT   VARIANT     591    591       P -> L (in dbSNP:rs36214022).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060693.
FT   VARIANT     622    622       I -> M (in dbSNP:rs36215047).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060694.
FT   VARIANT     941    941       M -> T. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040423.
FT   VARIANT     977    977       R -> W. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040424.
FT   VARIANT     978    978       K -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040425.
FT   VARIANT     993    993       Y -> C. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040426.
FT   VARIANT     994    994       D -> E. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040427.
FT   VARIANT    1005   1005       E -> Q. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040428.
FT   VARIANT    1007   1007       D -> Y. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040429.
FT   VARIANT    1008   1008       L -> P. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040430.
FT   VARIANT    1010   1010       R -> C (in dbSNP:rs371784492).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040431.
FT   VARIANT    1018   1018       T -> A. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040432.
FT   VARIANT    1272   1272       M -> I (in dbSNP:rs56169226).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040433.
FT   VARIANT    1346   1346       S -> N (in dbSNP:rs1056719).
FT                                {ECO:0000269|PubMed:15164053,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:7828849,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_040434.
FT   VARIANT    1405   1405       G -> V (in dbSNP:rs36220450).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_040435.
FT   MUTAGEN      42     42       K->A: Loss of activity, apoptotic
FT                                function and of autophosphorylation.
FT                                {ECO:0000269|PubMed:11579085,
FT                                ECO:0000269|PubMed:7828849}.
FT   MUTAGEN     289    289       S->A: Loss of phosphorylation and
FT                                significant increase in proapoptotic
FT                                activity.
FT   MUTAGEN     289    289       S->E: Reduction in proapoptotic activity.
FT   MUTAGEN     308    308       S->A: Elevated Ca(2+)-calmodulin binding
FT                                and Ca(2+)-calmodulin-independent kinase
FT                                activity. Increases apoptotic activity.
FT                                {ECO:0000269|PubMed:11579085}.
FT   MUTAGEN     308    308       S->D: Reduced Ca(2+)-calmodulin binding
FT                                and Ca(2+)-calmodulin-independent kinase
FT                                activity. Decreases apoptotic activity.
FT                                {ECO:0000269|PubMed:11579085}.
FT   MUTAGEN     313    313       S->A: Minimal effect on activity.
FT                                {ECO:0000269|PubMed:11579085}.
FT   CONFLICT    490    490       Y -> H (in Ref. 3; BAC87163).
FT                                {ECO:0000305}.
FT   CONFLICT   1217   1217       S -> G (in Ref. 4; CAH18690).
FT                                {ECO:0000305}.
FT   HELIX         9     11       {ECO:0000244|PDB:4PF4}.
FT   STRAND       13     21       {ECO:0000244|PDB:4PF4}.
FT   STRAND       23     32       {ECO:0000244|PDB:4PF4}.
FT   TURN         33     35       {ECO:0000244|PDB:4PF4}.
FT   STRAND       38     46       {ECO:0000244|PDB:4PF4}.
FT   STRAND       48     51       {ECO:0000244|PDB:2W4J}.
FT   STRAND       53     56       {ECO:0000244|PDB:4PF4}.
FT   HELIX        58     70       {ECO:0000244|PDB:4PF4}.
FT   STRAND       79     84       {ECO:0000244|PDB:4PF4}.
FT   STRAND       86     94       {ECO:0000244|PDB:4PF4}.
FT   HELIX       101    107       {ECO:0000244|PDB:4PF4}.
FT   STRAND      108    110       {ECO:0000244|PDB:3ZXT}.
FT   HELIX       113    132       {ECO:0000244|PDB:4PF4}.
FT   STRAND      134    136       {ECO:0000244|PDB:1JKT}.
FT   HELIX       142    144       {ECO:0000244|PDB:4PF4}.
FT   STRAND      145    148       {ECO:0000244|PDB:4PF4}.
FT   STRAND      150    154       {ECO:0000244|PDB:4PF4}.
FT   STRAND      157    159       {ECO:0000244|PDB:4PF4}.
FT   HELIX       162    164       {ECO:0000244|PDB:4UV0}.
FT   STRAND      169    171       {ECO:0000244|PDB:2W4J}.
FT   HELIX       181    183       {ECO:0000244|PDB:4PF4}.
FT   HELIX       186    189       {ECO:0000244|PDB:4PF4}.
FT   HELIX       197    212       {ECO:0000244|PDB:4PF4}.
FT   HELIX       222    230       {ECO:0000244|PDB:4PF4}.
FT   HELIX       238    241       {ECO:0000244|PDB:4PF4}.
FT   STRAND      242    244       {ECO:0000244|PDB:1P4F}.
FT   HELIX       246    255       {ECO:0000244|PDB:4PF4}.
FT   TURN        260    262       {ECO:0000244|PDB:4PF4}.
FT   HELIX       266    271       {ECO:0000244|PDB:4PF4}.
FT   TURN        273    275       {ECO:0000244|PDB:4PF4}.
FT   HELIX       280    288       {ECO:0000244|PDB:4B4L}.
FT   HELIX       293    302       {ECO:0000244|PDB:4B4L}.
FT   HELIX       304    318       {ECO:0000244|PDB:1YR5}.
SQ   SEQUENCE   1430 AA;  160046 MW;  E2C4246E7C78A6D2 CRC64;
     MTVFRQENVD DYYDTGEELG SGQFAVVKKC REKSTGLQYA AKFIKKRRTK SSRRGVSRED
     IEREVSILKE IQHPNVITLH EVYENKTDVI LILELVAGGE LFDFLAEKES LTEEEATEFL
     KQILNGVYYL HSLQIAHFDL KPENIMLLDR NVPKPRIKII DFGLAHKIDF GNEFKNIFGT
     PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANVS AVNYEFEDEY
     FSNTSALAKD FIRRLLVKDP KKRMTIQDSL QHPWIKPKDT QQALSRKASA VNMEKFKKFA
     ARKKWKQSVR LISLCQRLSR SFLSRSNMSV ARSDDTLDEE DSFVMKAIIH AINDDNVPGL
     QHLLGSLSNY DVNQPNKHGT PPLLIAAGCG NIQILQLLIK RGSRIDVQDK GGSNAVYWAA
     RHGHVDTLKF LSENKCPLDV KDKSGEMALH VAARYGHADV AQLLCSFGSN PNIQDKEEET
     PLHCAAWHGY YSVAKALCEA GCNVNIKNRE GETPLLTASA RGYHDIVECL AEHGADLNAC
     DKDGHIALHL AVRRCQMEVI KTLLSQGCFV DYQDRHGNTP LHVACKDGNM PIVVALCEAN
     CNLDISNKYG RTPLHLAANN GILDVVRYLC LMGASVEALT TDGKTAEDLA RSEQHEHVAG
     LLARLRKDTH RGLFIQQLRP TQNLQPRIKL KLFGHSGSGK TTLVESLKCG LLRSFFRRRR
     PRLSSTNSSR FPPSPLASKP TVSVSINNLY PGCENVSVRS RSMMFEPGLT KGMLEVFVAP
     THHPHCSADD QSTKAIDIQN AYLNGVGDFS VWEFSGNPVY FCCYDYFAAN DPTSIHVVVF
     SLEEPYEIQL NQVIFWLSFL KSLVPVEEPI AFGGKLKNPL QVVLVATHAD IMNVPRPAGG
     EFGYDKDTSL LKEIRNRFGN DLHISNKLFV LDAGASGSKD MKVLRNHLQE IRSQIVSVCP
     PMTHLCEKII STLPSWRKLN GPNQLMSLQQ FVYDVQDQLN PLASEEDLRR IAQQLHSTGE
     INIMQSETVQ DVLLLDPRWL CTNVLGKLLS VETPRALHHY RGRYTVEDIQ RLVPDSDVEE
     LLQILDAMDI CARDLSSGTM VDVPALIKTD NLHRSWADEE DEVMVYGGVR IVPVEHLTPF
     PCGIFHKVQV NLCRWIHQQS TEGDADIRLW VNGCKLANRG AELLVLLVNH GQGIEVQVRG
     LETEKIKCCL LLDSVCSTIE NVMATTLPGL LTVKHYLSPQ QLREHHEPVM IYQPRDFFRA
     QTLKETSLTN TMGGYKESFS SIMCFGCHDV YSQASLGMDI HASDLNLLTR RKLSRLLDPP
     DPLGKDWCLL AMNLGLPDLV AKYNTSNGAP KDFLPSPLHA LLREWTTYPE STVGTLMSKL
     RELGRRDAAD FLLKASSVFK INLDGNGQEA YASSCNSGTS YNSISSVVSR
//
